Edgar Carnero Contentti1, Juan Ignacio Rojas2, Edgardo Cristiano3, Vanessa Daccach Marques4, José Flores-Rivera5, Marco Lana-Peixoto6, Carlos Navas7, Regina Papais-Alvarenga8, Douglas K Sato9, Ibis Soto de Castillo10, Jorge Correale11. 1. Neuroimmunology Unit, Department of Neuroscience, Hospital Alemán, Buenos Aires, Argentina. Electronic address: ecarnerocontentti@hospitalaleman.com. 2. Centro de Esclerosis Múltiple de Buenos Aires (CEMBA), Buenos Aires, Argentina; Neurology Service, Hospital Universitario de CEMIC, Buenos Aires, Argentina. 3. Centro de Esclerosis Múltiple de Buenos Aires (CEMBA), Buenos Aires, Argentina. 4. Department of Neurosciences and Behavioral Sciences, Hospital das Clínicas, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. 5. National Institute of Neurology and Neurosurgery, ABC Medical Center, Mexico City, Mexico. 6. Department of Neurology, Federal University of Minas Gerais Medical School, Belo Horizonte, Brazil. 7. Clinica Enfermedad Desmielinizante, Clinica Universitaria Colombia, Colombia. 8. Hospital da Lagoa, University of Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil. 9. Brain Institute of Rio Grande do Sul, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil. 10. Neurology Department, Hospital Universitario de Maracaibo, Maracaibo, Bolivarian Republic of Venezuela. 11. Department of Neurology, Fleni, Buenos Aires, Argentina. Electronic address: jcorreale@fleni.org.ar.
Abstract
BACKGROUND: During the last two decades, neuromyelitis optica spectrum disorder (NMOSD) has undergone important changes, with new diagnostic markers and criteria, better recognition of clinical phenotypes, better disease prognosis and new therapeutic approaches. Consequently, management of NMOSD patients in Latin American (LATAM) has become more complex and challenging in clinical practice. In making these consensus recommendations, the aim was to review how the disease should be managed and treated among LATAM patients, in order to improve long-term outcomes in these populations. METHODS: A panel of LATAM neurologists who are experts in demyelinating diseases and dedicated to management and care of NMOSD patients gathered virtually during 2019 and 2020 to make consensus recommendations on management and treatment of NMOSD patients in LATAM. To achieve this consensus, the RAND/UCLA methodology for reaching formal consensus was used. RESULTS: The recommendations focused on diagnosis and differential diagnoses, disease prognosis, tailored treatment, identification of suboptimal treatment response and special circumstances management. They were based on published evidence and expert opinions. CONCLUSIONS: The recommendations of these consensus guidelines seek to optimize management and specific treatment of NMOSD patients in LATAM.
BACKGROUND: During the last two decades, neuromyelitis optica spectrum disorder (NMOSD) has undergone important changes, with new diagnostic markers and criteria, better recognition of clinical phenotypes, better disease prognosis and new therapeutic approaches. Consequently, management of NMOSD patients in Latin American (LATAM) has become more complex and challenging in clinical practice. In making these consensus recommendations, the aim was to review how the disease should be managed and treated among LATAMpatients, in order to improve long-term outcomes in these populations. METHODS: A panel of LATAM neurologists who are experts in demyelinating diseases and dedicated to management and care of NMOSD patients gathered virtually during 2019 and 2020 to make consensus recommendations on management and treatment of NMOSD patients in LATAM. To achieve this consensus, the RAND/UCLA methodology for reaching formal consensus was used. RESULTS: The recommendations focused on diagnosis and differential diagnoses, disease prognosis, tailored treatment, identification of suboptimal treatment response and special circumstances management. They were based on published evidence and expert opinions. CONCLUSIONS: The recommendations of these consensus guidelines seek to optimize management and specific treatment of NMOSD patients in LATAM.
Authors: Edgar Carnero Contentti; Guillermo Delgado-García; Juan Criniti; Pablo A López; Juan Pablo Pettinicchi; Edgardo Cristiano; Jimena Miguez; Edgar Patricio Correa-Díaz; Marcelo Oswaldo Álvarez Pucha; Joselyn Elizabeth Miño Zambrano; Enrique Gómez-Figueroa; Verónica Rivas-Alonso; José Flores-Rivera; Verónica Tkachuk; Alejandro Caride; Juan Ignacio Rojas Journal: Front Immunol Date: 2021-02-23 Impact factor: 7.561
Authors: Edgar Carnero Contentti; Pablo A Lopez; Juan Pablo Pettinicchi; Juan Criniti; Agustín Pappolla; Jimena Miguez; Liliana Patrucco; Edgardo Carnero Contentti; Susana Liwacki; Verónica Tkachuk; María E Balbuena; Carlos Vrech; Norma Deri; Jorge Correale; Mariano Marrodan; María C Ysrraelit; Felisa Leguizamon; Geraldine Luetic; María L Menichini; Darío Tavolini; Carolina Mainella; Gisela Zanga; Marcos Burgos; Javier Hryb; Andrés Barboza; Luciana Lazaro; Ricardo Alonso; Nora Fernández Liguori; Débora Nadur; Aníbal Chercoff; Marina Alonso Serena; Alejandro Caride; Friedemann Paul; Juan I Rojas Journal: Mult Scler J Exp Transl Clin Date: 2021-08-20